Michael Egge secures regulatory clearances for transformative global transactions and defends clients in high stakes cross-border investigations.

Leveraging more than 30 years of experience and a broad international perspective, Mr. Egge advises market leaders on a full spectrum of their most complex antitrust challenges, including investigations of:

  • Strategic transactions
  • Alleged cartel conduct
  • Conduct investigations brought by US and European enforcers 

Mr. Egge is widely regarded for his experience in clearing major transactions that require navigating merger control requirements around the world. He has appeared and argued before antitrust authorities in countries across North America, South America, Europe, and Asia. 

A recognized leader at the firm, Mr. Egge is Chair of the firm’s Global Antitrust & Competition Practice and has played a pivotal role in building one of the most comprehensive global antitrust practice platforms in the world today. From 2006 to 2015, he led Latham’s Global Antitrust & Competition Practice Group, including three years (2012-2015) resident in the Brussels office, where he helped expand Latham & Watkins’ practice before the European Commission. Mr. Egge was Managing Partner of the Washington, D.C. office from 2016 to 2020, and he served on the firm’s Executive Committee from 2020 to 2024.

Mr. Egge speaks frequently on antitrust issues and has served in a variety of leadership positions within the American Bar Association’s Antitrust Law Section, including as a member of its governing Council, Co-Chair of the Annual Spring Meeting, Chair of the Merger Process Working Group, and Chair of several of its expert conferences.

He maintains an active pro bono practice, including on behalf of the Osteosarcoma Collaborative, a nonprofit organization for which he is a founding member that brings together data, researchers, patients, and families to find new cures for the disease.

Mr. Egge’s experience includes representing:

  • Bunge Limited, a US grains merchant manufacturer, in obtaining global merger control and FDI clearances in more than 30 jurisdictions for its planned US$34 billion merger with Viterra
  • EssilorLuxottica in:
    • Its US$6 billion acquisition of GrandVision
    • Acquiring US-based lab network Walman
  • GRAIL in its US$8 billion acquisition by Illumina and novel post-closing litigation at the FTC 
  • Siemens Healthineers in its US$16.4 billion acquisition of VarianMedical Systems 
  • Agrium in its US$36 billion merger of equals with PotashCorp of Saskatchewan to create Nutrien
  • Nestle Health Sciences in its acquisitions of Vital Proteins, Nature’s Bounty, and Orgain
  • Dairy Farmers of America in its US$433 million acquisition of Dean Foods
  • Time Warner Cable in its US$55 billion merger with Charter
  • American Airlines in its successful bid for antitrust immunity for its joint business alliance with Qantas Airways 
  • FMC Technologies in its US$13 billion merger with Technip SA
  • Siemens in its US$7.6 billion acquisition of Dresser-Rand
  • Leading players in the auto parts and chemical industries in securing amnesty protection

Bar Qualification

  • District of Columbia


  • JD, University of Virginia School of Law, 1991
    Notes Editor, Virginia Law Review
  • AB in Economics, College of William & Mary, 1988
    with high honors

Languages Spoken

  • Spanish